Who are MMF (Cellcept) and Steroids's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycophenolate mofetil, low dose steroid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mmf-cellcept-and-steroids.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MMF (Cellcept) and Steroids — Competitive Intelligence Brief

MMF (Cellcept) and Steroids (MMF (Cellcept) and Steroids) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant combination (inosine monophosphate dehydrogenase inhibitor + corticosteroid). Area: Immunology.

marketed Immunosuppressant combination (inosine monophosphate dehydrogenase inhibitor + corticosteroid) IMPDH type II; glucocorticoid receptor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

MMF (Cellcept) and Steroids (MMF (Cellcept) and Steroids) — University of Luebeck. MMF (mycophenolate mofetil) inhibits inosine monophosphate dehydrogenase to suppress T and B lymphocyte proliferation, while corticosteroids broadly suppress immune cell activation and inflammatory cytokine production.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MMF (Cellcept) and Steroids TARGET	MMF (Cellcept) and Steroids	University of Luebeck	marketed	Immunosuppressant combination (inosine monophosphate dehydrogenase inhibitor + corticosteroid)	IMPDH type II; glucocorticoid receptor
Mycophenolate mofetil, low dose steroid	Mycophenolate mofetil, low dose steroid	Kyungpook National University Hospital	phase 3	Immunosuppressant combination (inosine monophosphate dehydrogenase inhibitor + corticosteroid)	IMPDH type II; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant combination (inosine monophosphate dehydrogenase inhibitor + corticosteroid) class)

Kyungpook National University Hospital · 1 drug in this class
University of Luebeck · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MMF (Cellcept) and Steroids — Competitive Intelligence Brief. https://druglandscape.com/ci/mmf-cellcept-and-steroids. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab